View by Specialty

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

Schizophrenia News

SPONSORED CONTENT
Save
SPONSORED CONTENT
February 07, 2024
4 min read
Save

An anomalous iris finding: A case of Wölfflin nodules

An anomalous iris finding: A case of Wölfflin nodules

Wölfflin nodules are light-colored, peripheral iris nodules that are found in 10% of healthy individuals and almost exclusively in patients with light irides.

SPONSORED CONTENT
January 18, 2024
3 min read
Save

Two antipsychotic drugs prolong QTc interval, may cause arrhythmias, sudden cardiac death

Two antipsychotic drugs prolong QTc interval, may cause arrhythmias, sudden cardiac death

The antipsychotic drugs quetiapine and haloperidol were associated with severe QT prolongation, ventricular arrhythmias and sudden cardiac death, researchers reported in HeartRhythm.

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

SPONSORED CONTENT
January 10, 2024
1 min read
Save

Weekly risperidone achieves similar drug levels as daily dose in phase 3 trial

Weekly risperidone achieves similar drug levels as daily dose in phase 3 trial

An investigational, weekly oral dose of risperidone for schizophrenia achieved drug levels comparable to daily Risperdal in a phase 3 study involving Lynx, a long-acting drug delivery platform developed by Lyndra Therapeutics.

SPONSORED CONTENT
January 04, 2024
1 min read
Save

FDA grants breakthrough device designation to digital therapeutic for schizophrenia

FDA grants breakthrough device designation to digital therapeutic for schizophrenia

The FDA has granted breakthrough device designation for CT-155, an investigational prescription digital therapeutic co-developed by Click Therapeutics and Boehringer Ingelheim to treat negative symptoms of schizophrenia.

SPONSORED CONTENT
December 28, 2023
1 min read
Save

Bristol Myers Squibb announces merger with Karuna Therapeutics

Bristol Myers Squibb announces merger with Karuna Therapeutics

Bristol Myers Squibb and Karuna Therapeutics Inc. announced a definitive merger agreement that includes Karuna’s lead asset, a muscarinic receptor agonist to treat schizophrenia and Alzheimer’s disease psychosis.

SPONSORED CONTENT
December 26, 2023
1 min read
Save

FDA clears neuromelanin MRI analysis platform for evaluating neurological disorders

FDA clears neuromelanin MRI analysis platform for evaluating neurological disorders

The FDA has cleared for marketing “the world’s first” cloud-based software for clinical analysis of neuromelanin-sensitive MRI scans, according to a press release from the manufacturer.

SPONSORED CONTENT
December 18, 2023
1 min read
Save

AbbVie acquires Cerevel, boosting roster of therapeutic candidates

AbbVie acquires Cerevel, boosting roster of therapeutic candidates

AbbVie Inc. has acquired Cerevel Therapeutics and its pipeline of clinical stage and preclinical neuroscience candidates in development to address conditions such as Parkinson’s disease, schizophrenia and mood disorders.

SPONSORED CONTENT
November 29, 2023
1 min read
Save

FDA accepts KarXT new drug application for treating schizophrenia

FDA accepts KarXT new drug application for treating schizophrenia

The FDA has accepted a new drug application from Karuna Therapeutics for KarXT, an investigational muscarinic antipsychotic for the treatment of schizophrenia in adults, the company announced in a press release.

SPONSORED CONTENT
November 07, 2023
1 min read
Save

$10M research initiative will fund research on neuroinflammation

$10M research initiative will fund research on neuroinflammation

The American Brain Foundation has announced the launch of a $10 million cross-disciplinary research initiative for neuroscientists to investigate the role of neuroinflammation in a wide range of neurologic and psychiatric brain diseases.

SPONSORED CONTENT
November 06, 2023
1 min read
Save

Brilaroxazine shows promise for schizophrenia in pivotal phase 3 trial

Brilaroxazine shows promise for schizophrenia in pivotal phase 3 trial

Brilaroxazine, a potential new treatment for schizophrenia, significantly improved symptoms and was well-tolerated in a pivotal phase 3 trial, according to a press release from its manufacturer.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails